Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2006;55:148-150; doi:10.1136/gut.2005.071787
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology.

COMMENTARY

Incretin

To be or not to be—an incretin or enterogastrone?

M Horowitz1, M A Nauck2

1 University of Adelaide, Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia
2 Internist/Gastroenterology/Endocrinology, Diabetology (DDG), Diabeteszentrum Bad Lauterberg, Kirchberg, Bad Lauterberg im Harz, Germany

Correspondence to:
Correspondence to:
Professor M Horowitz
Department of Medicine, North Terrace, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia; michael.horowitz@adelaide.edu.au


Glucagon-like peptide 1 does not comfortably fulfil the criterion of a gut derived factor responsible for an enhanced meal related insulin response; it appears logical to add the definition of a "physiological incretin hormone"

Keywords: glucagon-like peptide 1; exendin(9-39); incretin; enterogastrone; pyloric motility

The first 150 words of the full text of this article appear below.

Incretin hormones are gut derived peptides that augment the insulin releasing action of hyperglycaemia. In his seminal review, based on the 1978 Claude Bernard lecture, delivered at the European Association for the Study of Diabetes Meeting, Werner Creutzfeldt defined the term incretin as "an endocrine transmitter produced by the gastrointestinal tract which is: (a) released by nutrients, especially carbohydrates and (b) stimulates insulin secretion in the presence of glucose if exogenously infused in amounts not exceeding blood levels achieved after food ingestion".1 At that time, the best characterised incretin candidate was glucose dependent insulinotropic polypeptide (GIP), although there was evidence that GIP was not the only incretin.1,3 An incretin role for GIP was established, along the lines of Creutzfeldt’s definition,1 by intravenous infusion in healthy subjects, both alone and in combination with glucose, and demonstrating that the insulinotropic property of GIP was dependent on a permissive rise in blood . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Göke
Gut 2006 55: 243-251. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Chia, C. W., Carlson, O. D., Kim, W., Shin, Y.-K., Charles, C. P., Kim, H. S., Melvin, D. L., Egan, J. M. (2009). Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes. Diabetes 58: 1342-1349 [Abstract] [Full Text]  
  • Sutherland, K., Young, R. L., Cooper, N. J., Horowitz, M., Blackshaw, L. A. (2007). Phenotypic characterization of taste cells of the mouse small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1420-G1428 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs